Afinum acquires a majority stake in TISSO Naturprodukte GmbH, a specialized provider of holistic therapeutic nutritional supplements, alongside the existing shareholders and management.
AFINUM Achte Beteiligungsgesellschaft mbH & Co. KG, advised by AFINUM Management GmbH, signed an agreement with the shareholders Albert Hesse and Markus Junge at the beginning of September 2021 to invest and support the growth strategy of TISSO Naturprodukte GmbH (“TISSO” or the “Company”). With the support of Afinum, inter alia, the ongoing build-up of sales and distribution channels will be accelerated. The transaction was closed as of today.
The TISSO brand stands for high-quality nutritional supplements and a holistic therapy concept with a focus on the treatment of chronic health conditions. The company’s high degree of vertical integration is characterized by its own R&D, a deeply integrated production capacity as well as a unique network of therapists, which represents the cornerstone of the TISSO brand distribution strategy. In addition to its own product portfolio, TISSO supports customers as a B2B service provider in the field of innovative nutritional supplements with a holistic service approach, starting from product development to distribution and logistics functions.
The company has grown steadily in both areas in recent years and is planning a substantial expansion of capacities, including the planned opening of a second production site, which is already in execution. In this context, the previous sole shareholders, Albert Hesse and Markus Junge, have chosen Afinum as growth partner in an extremely competitive search process in order to optimally position the company for the next phase of its development. Decisive criteria for the selection of the new partner were a successful track record in supporting growth investments, the cultural fit of the organizations and Afinum’s concrete approach to a successful partnership and the achievement of the envisaged growth goals.
Markus Junge remains CEO and significantly invested in the company alongside founder Albert Hesse. In addition, it was jointly decided to provide key management personnel with the opportunity to invest in the company as part of the transaction.
The investment in TISSO is the twelfth transaction of AFINUM Achte Beteiligungsgesellschaft mbH & Co. KG. and strategically rounds off the fund’s portfolio. In July, the investment in evitria, also active in the healthcare sector, was sold to the Swedish Atlas Group after a very successful growth path.